IP Library Granted Patent US 11,065,267
Granted Patent B2
US 11,065,267 · App. 16/229,031 · Granted Jul 20, 2021

Lysophosphatidylcholine compositions

Inventors: Nils Hoem (Stamsund, NO); Finn Myhren (Stamsund, NO); Petter-Arnt Hals (Stamsund, NO); Armend Håti (Stamsund, NO)
Assignee: Aker BioMarine Antarctic AS
A61K31/685A23D9/00A23J7/00A23L33/115A61K31/202C11B1/025A23L33/12A23V2002/00C12P13/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,065,267
App. No.
16/229,031
Granted
Jul 20, 2021
Kind
B2
Abstract

The present invention provides marine lysophosphatidylcholine compositions for use in pharmaceuticals, nutraceuticals and functional foods, as well as methods for making marine lysophosphatidylcholine compositions.

Claims (40)

1. A marine lysophosphatidylcholine (LPC) composition characterized in comprising from about 20% to about 100% LPC w/w of the composition and an omega-3 fatty acid content of from 5% to 50% w/w of the composition, a ratio of EPA:DHA of from 1:1 to 3:1 on a w/w basis or a ratio of DHA:EPA of from 1:1 to 5:1 on a w/w basis, and a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis.

2. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition comprises from 60% to 100% LPC w/w of the composition.

3. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has an omega-3 fatty acid content of from 30% to 50% w/w of the composition.

4. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition comprises from 70% to 90% LPC w/w of the composition.

5. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has an omega-3 fatty acid content of from 35% to 45% w/w of the composition.

6. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition comprises from 20% to 50% LPC w/w of the composition.

7. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition comprises from 20% to 30% LPC w/w of the composition.

8. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has an omega-3 fatty acid content of from 5% to 20% w/w of the composition.

9. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has a phosphatidylcholine (PC) content of less than 10% w/w of the composition.

10. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has a phosphatidylethanolamine (PE) content of less than 1.2% w/w of the composition.

11. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has a neutral lipid content of from 5% to 65% w/w of the composition.

12. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition has a 2-LPC ether content of less than 1.0% w/w of the composition.

13. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition additionally has two or more of the following properties:

a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis;

a phosphatidylcholine (PC) content of less than 10% w/w of the composition; and

a phosphatidylethanolamine (PE) content of less than 1.2% w/w of the composition.

14. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition additionally has two or more of the following properties:

a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis;

a phosphatidylcholine (PC) content of less than 10% w/w of the composition;

a phosphatidylethanolamine (PE) content of less than 1.2% w/w of the composition;

a neutral lipid content of from 5% to 65% w/w of the composition; and

a 2-LPC ether content of less than 1.0% w/w of the composition.

15. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition additionally has three or more of the following properties:

a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis;

a phosphatidylcholine (PC) content of less than 10% w/w of the composition;

a phosphatidylethanolamine (PE) content of less than 1.2% w/w of the composition;

a neutral lipid content of from 5% to 65% w/w of the composition; and

a 2-LPC ether content of less than 1.0% w/w of the composition.

16. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition additionally has four or more of the following properties:

a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis;

a phosphatidylcholine (PC) content of less than 10% w/w of the composition;

a phosphatidylethanolamine (PE) content of less than 1.2% w/w of the composition;

a neutral lipid content of from 5% to 65% w/w of the composition; and

a 2-LPC ether content of less than 1.0% w/w of the composition.

17. The marine lysophosphatidylcholine (LPC) composition of claim 1 , wherein the composition additionally has the following properties:

a 2-LPC:1-LPC ratio of from 1:8 to 18:1 on a w/w basis;

a phosphatidylcholine (PC) content of less than 10% w/w of the composition;

a phosphatidylethanolamine (PE) content of less than 1.2% w/w of the composition;

a neutral lipid content of from 5% to 65% w/w of the composition; and

a 2-LPC ether content of less than 1.0% w/w of the composition.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: AKER BIOMARINE ANTARCTIC AS
To: AKER BIOMARINE HUMAN INGREDIENTS AS
Reel/Frame 066703/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2020
From: HOEM, NILS; MYHREN, FINN; HALS, PETTER-ARNT; HATI, ARMEND
To: AKER BIOMARINE ANTARCTIC AS
Reel/Frame 054426/0217 →
Continuity (3)
Provisional Application 62608891 · Dec 21, 2017
Provisional Application 62725683 · Aug 31, 2018
Related Publication 20190201424A1 · Jul 4, 2019